Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 202.12

+1.5%

10:59 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (10934)	11/10/1997 9:09:00 AM
From: Henry Niman	Read Replies (1) of 32384

chirodoc, I would put Targretin into the blockbuster category. Targretin is actually a partner for TZDs such as Rezulin. Rezulin is clearly in the "blockbuster" category. It was approved in the US in March and worldwide sales are projected to be $1.3 Billion next year. The drug is expensive, $1200 to $2400 per year, and targets the underlying cause of type II diabetes, insulin resisitance. Type II represents approximately 90% of diabetes and that is type form of the disease that is reaching epidemic levels. Western life styles, coupled with aging baby boomers are causing the market to explode. There are over 15 million diabetics in the US alone and reports of worldwide increases are widespread. The threshold for defining diabtetes has recently been lowered, and Rezulin is currently in prevention trials, which certainly makes sense from the treatment side. I expect type II diabetics, as well as high risk patients, to take a TZD/Rexinoid combo. So far the only competion in the rexinoid area is AGN, and LGND gets royalties on sales of those compounds also.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next